Албунорм 5%

Основна информация

  • Търговско наименование:
  • Албунорм 5% (Albunorm 5%)
  • INN (Международно Name):
  • Albumin
  • дозиране:
  • 50 g/l - 100 ml; - 250 ml; - 500 ml
  • Лекарствена форма:
  • инфузионен разтвор
  • Композиция:
  • инфузионен разтвор 50 g/l - 100 ml; - 250 ml; - 500 ml
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Албунорм 5% (Albunorm 5%)
    България
  • Език:
  • български

Терапевтична информация

  • Терапевтична група:
  • Plasma substitutes and plasma protein fractions

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Последна актуализация:
  • 09-08-2016

Листовка за пациента

28-3-2018

Orphan designation:  Recombinant fusion protein linking coagulation factor VIIa with albumin,  for the: Treatment of congenital factor VII deficiency

Orphan designation: Recombinant fusion protein linking coagulation factor VIIa with albumin, for the: Treatment of congenital factor VII deficiency

On 7 October 2013, orphan designation (EU/3/13/1188) was granted by the European Commission to CSL Behring GmbH, Germany, for recombinant fusion protein linking coagulation factor VIIa with albumin for the treatment of congenital factor VII deficiency.

Europe - EMA - European Medicines Agency

28-3-2018

Orphan designation:  Recombinant fusion protein linking human coagulation factor VIIa with human albumin,  for the: Treatment of haemophilia B

Orphan designation: Recombinant fusion protein linking human coagulation factor VIIa with human albumin, for the: Treatment of haemophilia B

On 13 May 2011, orphan designation (EU/3/11/863) was granted by the European Commission to CSL Behring GmbH, Germany, for recombinant fusion protein linking human coagulation factor VIIa with human albumin for the treatment of haemophilia B.

Europe - EMA - European Medicines Agency

1-12-2017

Albumin Human 25 Percent Solution (AlbuRx 25): Product Information Advisory - Fading Print On Label

Albumin Human 25 Percent Solution (AlbuRx 25): Product Information Advisory - Fading Print On Label

Potential for fading print, with more effect on the expiration dating on the patient tear off portion of the vial label.

FDA - U.S. Food and Drug Administration

22-12-2017

ALBUTEIN (Albumin (Human)) Injection, Solution [GRIFOLS USA, LLC]

ALBUTEIN (Albumin (Human)) Injection, Solution [GRIFOLS USA, LLC]

Updated Date: Dec 22, 2017 EST

US - DailyMed

22-12-2017

HUMAN ALBUMIN GRIFOLS (Albumin (Human)) Solution [GRIFOLS USA, LLC]

HUMAN ALBUMIN GRIFOLS (Albumin (Human)) Solution [GRIFOLS USA, LLC]

Updated Date: Dec 22, 2017 EST

US - DailyMed

3-11-2017

ALBUMINAR-25 (Albumin (Human)) Solution [CSL Behring LLC]

ALBUMINAR-25 (Albumin (Human)) Solution [CSL Behring LLC]

Updated Date: Nov 3, 2017 EST

US - DailyMed

4-8-2017

BUMINATE (Albumin Human) Injection, Solution [Baxalta US Inc.]

BUMINATE (Albumin Human) Injection, Solution [Baxalta US Inc.]

Updated Date: Aug 4, 2017 EST

US - DailyMed

4-8-2017

FLEXBUMIN (Albumin Human) Solution [Baxalta US Inc.]

FLEXBUMIN (Albumin Human) Solution [Baxalta US Inc.]

Updated Date: Aug 4, 2017 EST

US - DailyMed

28-6-2017

ALBUKED (Albumin (Human)) Solution [KEDRION BIOPHARMA, INC.]

ALBUKED (Albumin (Human)) Solution [KEDRION BIOPHARMA, INC.]

Updated Date: Jun 28, 2017 EST

US - DailyMed

28-6-2017

PLASBUMIN (Albumin (Human)) Solution [GRIFOLS USA, LLC]

PLASBUMIN (Albumin (Human)) Solution [GRIFOLS USA, LLC]

Updated Date: Jun 28, 2017 EST

US - DailyMed